Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT-Reference-Cited by-同舟云学术

Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT

Published:2023-01-31 Issue:5 Volume:48 Page:445-447
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Li Siqi¹,Wang Hongrong²,Wang Guanyun¹,Lu Xia¹,Yang Jigang¹

Affiliation:

1. Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University, Beijing, China

2. Department of Nuclear Medicine, Beijing Boren Hospital, Beijing, China.

Abstract

Abstract 18F-FDG PET/CT was performed to evaluate possible recurrent B-cell lymphoblastic lymphoma in a 34-year-old man. The images showed multiple foci of increased activity in the nerve root and peripheral nerve. A biopsy confirmed the diagnosis of neurolymphomatosis. After receiving chemotherapy, PET/CT showed progressive disease. The patient subsequently received the CD-19 chimeric antigen receptor T-cell therapy. A follow-up PET/CT acquired 30 days after chimeric antigen receptor T-cell therapy revealed no abnormal FDG activity.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference16 articles.

1. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab;Neuro Oncol,2010

2. Neurolymphomatosis: an international primary CNS lymphoma collaborative group report;Blood,2010

3. Bilateral facial nerve palsy in acute B cell lymphoblastic leukemia: a case report and review of the literature;Indian J Hematol Blood Transfus,2016

4. Trigeminal nerve involvement in T-cell acute lymphoblastic leukemia: value of MR imaging;Eur J Radiol,2002

5. Neurolymphomatosis;Neuro Oncol,2003